Breakfast Brief: Melanoma – New developments in sight
Melanoma has long been at the cutting edge of immuno-oncology research, which will likely continue. The way for future headlines is already paved.
Melanoma has long been at the cutting edge of immuno-oncology research, which will likely continue. The way for future headlines is already paved.
In this Breakfast Brief, Prof. Dr. Olivier Michielin, Central University Hospital (CHUV), Lausanne, presents melanoma highlights of ESMO Congress 2018
The combination of ipilimumab + nivolumab induces high response rates and improved overall survival in late stage melanoma (OpACIN). However, toxicity was high with 90% grade 3/4 immune-related adverse events (irAEs).
New results show that an alternative schedule is able to reduce the toxicity, while keeping the high response rate.
Another investigation sheds some light on basic processes of the tumour and could be able to provide new biomarkers (COMBI-AD).
Source: ESMO Conference 2018
The following abstracts are discussed:
#LBA42: Blank CU et al.: LBA42 – OpACIN-neo – A Multicenter Phase 2 Study to identify the Optimal neo-Adjuvant Combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO)
#LBA43: Long GV et al.: Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma
#LBA44: Hodi FS et al.: LBA44 – Overall survival at 4 years of follow-up in a phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
#12440: Ascierto PA et al.: KEYNOTE-022 Part 3: Phase 2 Randomized Study of 1L Dabrafenib (D) and Trametinib (T) Plus Pembrolizumab (Pembro) or Placebo (PBO) for BRAF-Mutant Advanced Melanoma